Who Paid My Doc
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756
Research payments
$4,665,884
Through program year 2024, $4,665,884 in research payments was reported against A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756, across 3,377 payments, paid by Merck Sharp & Dohme Corporation.
- Paid by
- Merck Sharp & Dohme Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $328,583 | 62 |
| 2020 | Research | $3,002,502 | 2,653 |
| 2019 | Research | $1,334,798 | 662 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Joyce O'Shaughnessy Dallas, TX Named on 1,368 payments
- Kristi McIntyre Dallas, TX Named on 474 payments
- Debra Patt Austin, TX Named on 408 payments
- Jay Andersen Portland, OR Named on 197 payments
- Rachel Swart Tucson, AZ Named on 126 payments
- Sasha Strain Tyler, TX Named on 115 payments
- Michael Danso Norfolk, VA Named on 91 payments
- Denise Yardley Nashville, TN Named on 73 payments
- Michael Meshad Mobile, AL Named on 65 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.